Lung Cancer Phase 3 DESTINY-Lung04 Study: T-DXd as First-Line Therapy for HER2-Mutated NSCLC Mar 30, 2023
Lung Cancer RESILIENT Phase 2 study: Adverse Effects of Second-Line Liposomal Irinotecan in SCLC Mar 30, 2023
Lung Cancer Phase 2 ZENITH20-4 Study: Poziotinib to Treat Naive NSCLC with HER2 Exon 20 Mutations Mar 30, 2023
Leukemia Ibrutinib: A Promising Therapy for Patients with Early Stage Chronic Lymphocytic Leukemia Mar 29, 2023
